Open AccessNeutropenia Associated with Vincristine and L‐Asparaginase Induction Chemotherapy for Canine Lymphoma
Author(s) -
Northrup Nicole C.,
Rassnick Kenneth M.,
Snyder Laura A.,
Stone Michael S.,
Kristal Orna,
Cotter Susan M.,
Moore Antony S.
Publication year - 2002
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2002.tb02389.x
Subject(s) - medicine , neutropenia , vincristine , absolute neutrophil count , canine lymphoma , lymphoma , gastroenterology , vomiting , toxicity , chemotherapy , cyclophosphamide
Vincristine (VCR) and L‐asparaginase (L‐ASP) are commonly used to treat canine lymphoma. As single agents, these drugs are not myelosuppressive. However, in combination, VCR and L‐ASP cause severe neutropenia in some dogs. It has been recommended that L‐ASP be administered 12–24 hours after VCR to minimize toxicity. The purpose of this retrospective study was to determine the prevalence of neutropenia after VCR/l‐ASP induction therapy for canine lymphoma and to evaluate risk factors for myelosup‐pression, especially the interval between VCR and L‐ASP administration. Medical records of 147 dogs were reviewed. L‐ASP was given 0 (n = 50), 6 (n = 23), 18 (n = 20), or 24 (n = 54) hours after VCR. Forty percent of the dogs were neutropenic 7 days after VCR/L‐ASP, and 18% had neutrophil counts of